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ABSTRACT
Chromatin is a system of proteins, RNA, and DNA
that interact with each other to organize and regulate
genetic information within eukaryotic nuclei. Chro-
matin proteins carry out essential functions: pack-
ing DNA during cell division, partitioning DNA into
sub-regions within the nucleus, and controlling lev-
els of gene expression. There is a growing interest
in manipulating chromatin dynamics for applications
in medicine and agriculture. Progress in this area re-
quires the identification of design rules for the chro-
matin system. Here, we focus on the relationship be-
tween the physical structure and function of chro-
matin proteins. We discuss key research that has elu-
cidated the intrinsic properties of chromatin proteins
and how this information informs design rules for
synthetic systems. Recent work demonstrates that
chromatin-derived peptide motifs are portable and in
some cases can be customized to alter their func-
tion. Finally, we present a workflow for fusion protein
design and discuss best practices for engineering
chromatin to assist scientists in advancing the field
of synthetic epigenetics.
CHROMATIN ENGINEERING: AN IMPORTANT AND
CHALLENGING UNDERTAKING
Chromatin is a dynamic nuclear structure that has a central
role in eukaryotic development. The mechanics of this an-
cient, highly conserved system (1,2) are primarily driven by
the physical structure and interactions of its components,
proteins and nucleic acids. Electrostatic bonds and hy-
drophobic interactions determine the composition ofmulti-
part subunits such as nucleosomes, transcription initiation
complexes, and repressive complexes. Because of its impact
on tissue development, chromatin has great potential for en-
gineering cell populations. Chromatin proteins exert strong
and flexible control over cohorts of genes that determine
cell fate and tissue organization. Chromatin states, i.e. ac-
tively transcribed and silenced, can switch from one to the
other. At the same time chromatin-mediated regulation can
be very stable, persisting over many cycles of DNA replica-
tion and mitosis. The latter property is a mode of epigenetic
inheritance, where cellular information that is not encoded
in the DNA sequence is passed from mother to daughter
cells. The stability of chromatin states allows specific epige-
netic programs to scale with tissue development in multicel-
lular organisms.
Early biochemical and protein structure studies of the nu-
cleosome (3) have generated a high resolution model that
has persisted over time. A single nucleosome includes a
complex of eight histone proteins arranged in a spiral-like
disc. Each histone contains a C-terminal globular region
composed of helix-turn-helix motifs called the histone fold
domain, and an unfolded N-terminal tail (4) (Figure 1A).
Within each nucleosome, a tetramer of histones H3 and H4
is stacked between two dimers of histones H2A and H2B
(Figure 1B). The stacking model can be viewed as a data-
guided 3D animation, created by D. Berry (5). Roughly 200
bp of DNA is wrapped twice around the histone complex.
Histones H1/H5 interact with the ‘linker’ DNA at the entry
and exit site of the wrapped DNA (6,7). Nucleosome struc-
tures appear repeatedly along each linear chromosome in
eukaryotic cells and support higher-order packaging of the
entire genome (Figure 1B).
In natural systems, the histone octamer is modular and
dynamic. There are four natural variants of H2A and H3
with distinct amino acid sequences (reviewed in 8,9), while
histones H4 and H2B are largely invariant (10). Substitu-
tions of H2A and H3 with variants in the octamer com-
plex play critical roles in gene regulation, DNA replica-
tion, and chromosome structure (4). Kinetic studies of
fluorescently labelled histones have shown that H3 and
H4 turnover is very slow. In contrast, exchange of the
H2A/H2B dimer occurs within a few minutes to two hours
(11). Exchange of histone H1 occurs in under two minutes
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Figure 1. The nucleosome, the core subunit of chromatin, is a modular
protein complex. (A) 3D model based on K. Luger’s 1997 X-ray crys-
tallography data, PDB ID: 1AOI (3). (B) The cartoon abstraction shows
the general shape of each histone: the Z-shape is the globular region and
the thinner line is the unfolded N-terminal tail. A H3/H4 tetramer (green
and blue) and two H2A/H2B dimers (orange and pink) bind across ∼120
bp DNA and become stacked to form a solenoid, DNA-wrapped struc-
ture (for a data-based animation, see (5)). The lower-right cartoon depicts
higher-order packaging of nucleosomes into a metaphase chromosome.
(12). Addition and erasure of post-translational modifica-
tions (PTMs) is another highly dynamic feature of nucle-
osomes. Histone-modifying enzymes covalently link or re-
move small molecules at the side chains of specific amino
acids within each histone. These modifications take place
mostly in the unfolded tails, while a few occur in the glob-
ular domain. Over 15 known modifications include lysine
acetylation (Kac), lysine methylation (Kme), serine phos-
phorylation (Sp), sumoylation (su), ubiquitination (ub) and
crotonylation (cr) (13) (Figure 2). In total, over 50 differ-
ent amino acid positions are known to be modified. Certain
types of PTMs result in transcriptional silencing of a nearby
gene, while others enable activation.
Collectively, PTMs make up a rich set of biological in-
formation in which single or combinations of molecular
tags recruit histone-binding effectors to target genes. By the
year 2000, dozens of PTMs had been documented, rela-
tionships between histone modifications and gene regula-
tion states began to materialize, and the term ‘histone code’
was coined by Brian Strahl and David Allis (14–17). Since
the first report of the structure of the histone-binding do-
main fromP/CAF in 1999 (18) a plethora of other 3D struc-
tures have become available to the scientific community. In-
vestigations of binding pocket specificity support the idea
that peptide motifs can distinguish one PTM from another
(19–21). These protein structure and interaction data can
be used by synthetic biologists to design artificial epigenetic
systems and to further confirm or correct aspects of the his-
tone codemodel. Taverna et al. provide an excellent detailed
review of lessons learned from the molecular structures of
PTM-binding domains (19).
In spite of its potential usefulness, chromatin is often per-
ceived by biological engineers as an impediment rather than
as an enabling tool. Cells are typically engineered by in-
tegrating exogenous, recombinant DNA into the chromo-
somes of the host cell. These transgenes include regulatory
components that are carefully designed to operate with pre-
determined kinetics. However, the transgene often becomes
subjected to the surrounding chromatin environment and
is mis-regulated (silenced or hyper-activated). The molec-
ular complexity of chromatin may give scientists the im-
pression that chromatin-mediated expression states are im-
possible to control. Chromatin complexes are often com-
posed of multiple subunits, which have several paralogs in a
single organism. For instance, Polycomb Repressive Com-
plex 1 (PRC1) appears as six sub-types that occupy different
genomic regions (22). Each of the PRC1 subunits may be
one of several distinct paralogs. Furthermore, the core sub-
unit of chromatin known as the nucleosome contains two
copies of four types of histones (H2A, H2B, H3, H4) (4),
two of which have multiple variants. Histones H3 and H2A
have eight and five known variants, respectively. The vari-
ants differ in primary sequence, genome distribution, and
expression in different tissues and phases of the cell cycle
(23,24). Compared to simpler biological principles such as
Watson–Crick base-pairing, the complex interactions that
govern the behavior of chromatin may seem less amenable
to bioengineering.
Is it worthwhile to attempt to engineer multi-layered sys-
tems like chromatin within a complex cellular milieu? Syn-
thetic biologists have demonstrated so far that such work
produces valuable new knowledge as well as useful innova-
tions (25,26). We believe that the current wealth of informa-
tion produced by decades of research in chromatin epige-
netics provides a sufficient platform to support engineering
efforts. In this review, we discuss how proteins and nucleic
acids that guide epigenetic regulation in nature have been
harnessed for custom-built systems. Specifically, we focus
on the molecular structures of chromatin proteins and how
our understanding of molecular interactions can be lever-
aged for chromatin engineering. We discuss best practices
for chromatin engineering endeavors and present a flexible,
standard workflow for efficient, high-throughput engineer-
ing of chromatin-derived proteins.
ENGINEERING NUCLEOSOMES, THE CORE SUB-
UNITS OF CHROMATIN
Early efforts to engineer nucleosomes used chemical reac-
tions to modify purified histones in vitro. Chemical liga-
tion (Figure 2B) has been used to attach synthetic, pre-
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Figure 2. Graphical survey of known histone posttranslational modifications and techniques for generating histone PTMs. (A) PTMs that have been
artificially generated are shown in red (28–38,40,43–46,49,63,150). Positions of methylation, acetylation, phosphorylation and other PTMs are shown
for each canonical histone. Other modifications (stars) include citrullination/deimination, ADP-ribosylation, propionylation, butyrylation, formylation,
proline isomerization, hydroxylation, malonylation, glutathionylation, crotonylation and succinylation (166). Globular, folded histone regions are shaded.
(B) Illustration of three general methods for generating histone PTMs. Chemical ligation adds pre-modified peptides to recombinant histone proteins.
The products are assembled with other histones and DNA to generate nucleosomes in vitro. Translation of mRNA using engineered tRNA synthetases
incorporate modified amino acid residues into genetically encoded amber stop codons (UAG) in the open reading frame of a custom sequence/histone.
Fusion enzymes are produced in cells by expressing aDNA-binding domain (DBD) in-frame with a histone-modifying enzyme (HME) or catalytic domain.
The fusion protein binds a DNA target and generates or erases PTMs at native nucleosomes.
modified peptides into recombinant histone proteins. A de-
tailed discussion of specific chemical methods is available
in (27). Chemical ligation has been used to generate his-
tones bearing acetylation at H3K4, 9, 14, 18, 23, H4K5,
8, 12, 16, tri-methylation at H3K9, and phosphorylation at
H3S10 (28–30). Soon after, methylation intermediates (one,
two or three methyl groups) were produced on analogs of
H3K9, 36, 79 and H4K20 (31). Chemical ligation, and sub-
sequently split inteins,were used to produce ubiquitinated
H2B (32,33). Semi-synthetic histones have enabled scien-
tists to build custom nucleosomes and nucleosome arrays to
investigate how isolated proteins engage with diverse chro-
matin templates (27).
Recent advances have allowed scientists to build modi-
fied histones via translation of mRNA (Figure 2B). Engi-
neered synthetases have been used to charge amber stop
codon-binding tRNAswith pre-modified amino acids. Dur-
ing translation, the modified amino acid is incorporated at
any position where a codon has been replaced with UAG
in a customized (recoded) mRNA sequence. Acetylation
at H2AK9, H2BK5 and K20, H3K56, K23 and K27, and
H4K16 were all recombinantly expressed in bacteria with
this method (34,35). Kim et al. demonstrated successful in-
corporation of a crotonyl group at position K11 in histone
H2B (36). Recently developed synthetases that charge tR-
NAs with propionyl-lysine, butyryl-lysine (37) and -N-2-
hydroxyisobutyryl-lysine (38) further broaden the spectrum
of expressed custom histones. In a landmark mammalian
cell study, Elsa¨sser et al. used a genetically-integrated re-
coded mRNA translation system to produce pre-modified
histones in E14 mouse embryonic stem cells. Six lysine
codons in the genes for histones H3.2 and H3.3 were re-
placed with amber stop codons. Incorporation of acetyl-
lysines at H3.3 positions 9, 23, 27, 37, 56 and 64 resulted
in the upregulation of 16 genes, including the locus for
the noncoding RNA Xist, compared to a wild type H3.3
parental line (39). This technology provides a powerful plat-
form to explore the impact of a variety of histone modifica-
tions, natural or novel, in the context of live cells.
Fusion proteins have been used to generate and erase
PTMs on endogenous histones, and to enhance or re-
press transcription at genomic sites in live cells. Histone-
modifying enzymes can be fused in-frame with a DNA-
binding domain (i.e. dCas9/gRNA, Gal4, LexA, TALE,
TetR and Zinc Finger) to generate silencing- or activation-
associated PTMs at a gene or non-coding locus (Figure
2B). Fusion enzymes have been used to repress gene ex-
pression through methylation of histones: H3K27 via En-
hancer of Zeste homologue 2 (EZH2) (40,41), EED (42)
andNuclear Effector (NUE) (43), methylation of H3K9 via
Suppressor of Variegation 3–9 homologue 1 (SUV39H1),
G9A (44), Kryptonite (KYP) (43), DNA methyltrans-
ferase via DMNT3B (42), lysine methyltransferase 1D
(EHMT1) (45); and methylation of H4K20 via TgSET8
(43). Gene repression has also been controlled by removal
of methyl groups from H3K4 via lysine demethylase 1A
(LSD1, KDM1A) (46,47), and removal of acetyl groups
from histones via histone deacetylase 4 (HDAC4) (37),
HDAC8, RPD3, silent information regulator 2 (Sir2a), and
Sin3a (43). Examples of gene-activating PTMs generated
by fusion proteins include acetylation of lysines via the
catalytic domain of p300 (48,49) and P/CAF (KAT2B)
(48). In a creative application of light-regulated peptides,
Konermann et al. controlled histone PTMs H3K9me1,
H4K20me3, H3K27me3, H3K9ac and H4K8ac with a
TALE-cryptochrome 2 fusion and its light-induced conju-
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gating binding partner CIB1 fusedwith a variety of catalytic
domains (43). Fusion protein-mediated histone modifica-
tion has been reviewed in detail in other excellent reviews
(26,50).
Fusion proteins have demonstrated great utility for test-
ing simple assumptions about the impact of histone PTMs
on gene expression. Further progress in the use of histone-
modifying fusion proteins to regulate genes requires care-
ful consideration of important contextual aspects: cross-
signaling between PTMs and interactions of specific PTM-
modifying enzymes with other enzymes. Cross-signaling be-
tween PTMs occurs when onemodification leads to the gen-
eration or erasure of another modification (51). This event
is mediated by enzymes that bind pre-existing histone mod-
ifications and then catalyze new PTMs (reviewed in 52–
54). A classic example is H3K9 methylation by the HP1
SUV39H1 complex.H3K9me3 is recognized byHP1, which
recruits SUV39H1, an enzyme that methylates K9 at neigh-
boring H3 histones (55). Other examples of crosstalk oc-
cur between distinct types of modifications. Phosphoryla-
tion of H3S10 induces Gcn5 to acetylate H3K14 in yeast
(56). H2B ubiquitination stimulates methylation of H3K4
and K79 via hDot1L (57). Complexes that contain SGF29,
NuA or HBO bind H3K4me3 and acetylate histones H3
andH4 (54). In the case of Rpd3S, cross-signaling promotes
the conversion of one gene expression state into another.
H3K27me3, which is associated with active transcriptional
elongation, is targeted by Rpd3S which removes acetyl
groups from histones H3 and H4 to promote silencing (58).
Cross-signaling can also be inhibitory, where the presence
of one PTM blocks the function of another. The activation-
associated mark H3K4me3 blocks interaction of the PRC2
complex with H3, prevents methylation of H3K27, and pre-
vents gene silencing (59). H3S10p disrupts binding ofDido3
with H3K4me3 (60) and enables progression through mito-
sis. The second contextual aspect we discuss here is the co-
recruitment of PTM-modifying enzymes. KRAB is a strong
repressor that has been widely used in early and recent work
to silence gene targets (e.g. see (41,42,61–64)). The conse-
quences of KRAB fusion-mediated regulation are compli-
cated by interactions with H3K9 methylases (via HP1) as
well as histone deacetylases (65). Unintended recruitment
of endogenous enzymes can be avoided in some cases by
using only the core catalytic domain of the histone mod-
ifier (e.g. p300 (48,49)). In summary, the wealth of infor-
mation from mechanistic studies such as those cited here
should be leveraged to design effective chromatin engineer-
ing strategies. Pre-existing PTMs at target loci should be
determined so that scientists can predict whether fusion en-
zyme activity will be blocked or enhanced. Recruitment of
PTM-modifying binding partners should either be taken
into account or avoided in experiments that aim to inves-
tigate mechanisms associated with individual PTMs.
ENGINEERING PROTEINS TO RECOGNIZE HISTONE
TAGS
PTM-binding proteins can be used to integrate information
from histone marks into engineered systems by physically
interacting with histone PTMs. In natural systems, PTM-
binding proteins act as effectors that regulate gene expres-
sion at sites that are enriched for the target histonemodifica-
tion. Here, we highlight four PTM-binding motifs that have
been used for chromatin engineering: the chromodomain
(CD), bromodomain (BRD), baculovirus inhibitor of apop-
tosis repeat (BIR) domain, and PHD finger. Several stud-
ies have demonstrated that these PTM-binding motifs re-
tain their intrinsic function as isolated peptides, and in some
cases after they are incorporated into a fusion protein (Ta-
ble 1). For a detailed discussion of other well-characterized
PTM-binding domains, see Park et al. (26).
The chromodomain (CD) motif interacts with methy-
lated histone lysine residues. 3D structure analyses and
binding assays have demonstrated that the HP1 chromod-
omain (66–68) and Polycomb chromodomain paralogs (68–
70) show preferential binding to their cognate PTM targets
in vitro. The CD consists of three  strands packed against a
C-terminal  helix, and a hydrophobic pocket that interacts
with methyl-lysine (Figure 3A) (66,68,69,71,72). Various
CD-containing proteins interact with histone H3 (K4, K9,
K27, K36 andK79) and histone H4 (K20) methylated once,
twice or three times (me1, me2, me3) (73). Structural studies
determined how heterochromatin protein 1 chromodomain
(HP1 CD) specifically recognizes trimethylated (me3) hi-
stone H3K9. K9me3 is buried in a binding pocket com-
prised of three aromatic residues, while four amino acids
preceding K9 interact with the chromodomain (67). Muta-
tional analysis of a Drosophila HP1 CD showed that the
hydrophobic binding cage is necessary for HP1 CD ligand
affinity (66). Side chain interactions between the H3 tail
and residues from HP1 form a zipper-like  sheet, under-
scoring the contribution of K9-adjacent histone residues to
HP1 CD binding. The Polycomb chromodomain (PCD) is
a different type of CD that preferentially binds H3K27me3
and has been shown to cross react with H3K9me3 in vitro
(71). Although they share high levels of sequence similarity,
five mammalian PCDs (CBX2, 4, 6, 7, 8) show significant
differences in binding preferences (70). Negatively charged
and hydrophobic surfaces distinguish two classes of mam-
malian PCDs that have high and low affinity, respectively,
for their histone ligands (74). Like HP1 CD, the CBXPCDs
have a conserved binding motif where a -strand from the
histone tail forms a  sheet with the CD. PCDs share a
unique binding site for A25, which fits into a hydropho-
bic pocket that will not tolerate any other amino acids. In
summary, the structural studies of chromodomains suggest
two general requirements for CD binding: a hydrophobic
pocket and a CD-histone beta sheet (Figure 3). Studies in
live cells have demonstrated that CD peptides retain in-
trinsic PTM-recognition activity within fusion proteins. In
Drosophila, fusion proteins containing beta-galactosidase
and either the HP1 CD (75) or the Polycomb CD (76) show
binding distributions on chromosomes that are similar to
the corresponding natural proteins. The PolycombCD from
CBX8 has been used to build a synthetic activator that stim-
ulates gene expression at H3K27me3-enriched genes in hu-
man cells (77,78), potentially counteracting oncogenic, re-
pressed chromatin states.
Bromodomains (BRDs) bind acetylated histones tails.
These motifs are typically 110 residues in length and ap-
pear in histone acetyltransferases and nucleosome remod-
elling complexes (79–81). Isolated BRD domains from
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Table 1. PTM-binding motifs that retain their intrinsic histone specificity in isolation or as a sub-domain within a synthetic or oncogenic fusion protein
Motif
Protein
(length, a.a.) Species Target PTM(s)
Experiments with isolated peptides
in vitro Peptide (a.a.)
Synthetic (S) and
oncogenic (O) fusions
studied in cells Peptide (a.a.)
CD HP1 (206) D. mel H3K9me2, 3 X-ray crystallography (66,67) FP
(68)
17–76 (S) CD-beta-gal (75) 1–95
CD Pc (390) D. mel H3K27me3 X-ray crystallography (68,69) 15–77, 23–77 (S) CD-beta-gal (76) 1–117
FP (68) 1–98
CD CBX8 (389) H. sap H3K27me3 (S) CD-VP64 (77,78) 1–62
M. musc H3K27me3 FP (M. musc) (70) 1–62




(O) BRD4-NUT (85) 1–719
BRD BPTF (3046) H. sap H4K12ac,
H4K16ac,
H4K20ac
X-ray crystallography, SPOT array,




BIR BIRC5 (142) H. sap H3T3p NMR (89) 1–120 n/r
PHD BPTF (3046) H. sap H3K4me3 X-ray crystallography, SPOT array,






H. sap H3K4me3 Peptide pulldown, fluorescence
microscopy, Co-IP, ITC (167)
1601–1660 (O) PHD-NUP98 (167) 1489–1690
PHD Dido3 (2256) M. musc H3K4me3 NMR, X-Ray crystallography,
fluorescence microscopy, peptide
pulldown, SPOT array, tryptophan
fluorescence (60)
266–325 (S) HA-DIDO (60) 1–528 (Dido1)
Dido1 (614)
Representative examples from published reports are included in the table. CD= chromodomain, BRD= bromodomain, FP= fluorescence polarization assay, ITC= isothermal
titration calorimetry, n/r = none reported. Lengths of proteins are from Uniprot.
Gcn5p, BRD2 and BRD4 interact with acetylated histone
tail peptides in 3D structure studies and in affinity assays
(79,80,82,83). Although there is a high degree of sequence
variation among the 61 known human BRD proteins, they
share a conserved tertiary structure consisting of a left-
handed bundle of four  helices linked by variable length
loops that surround the histone binding site (Figure 3B).
For instance, the BRD region of BRD2 contains a deep hy-
drophobic pocket contributes to the affinity for acetylated
lysines (82,83). Specificity is determined by the primary se-
quences of the variable loops (80) and by a hydrogen bond
between the oxygen of the acetyl carbonyl on the peptide
and the amide nitrogen of a conserved asparagine residue
(Asn407) (79). In some cases, BRDs recognize PTMs other
than acetylation (80). Natural bromodomains from BRD9,
CECR2 and TAF1 have been shown to bind to butyryl-
and crotonyllysine (84). Flynn et al. discovered a gain-of-
function mutation in BRD1 that conferred affinity for bu-
tyryl, with no loss of the intrinsic acetyl binding (84). Stud-
ies of a BRD fusion suggests that BRD can be used to
engineer proteins that bind acetyl-histones. BRD domains
confer histone-binding activity to the NUT protein in cells
where an oncogenic chromosome rearrangement fuses the
N-terminal BRD domains of BRD4 to NUT (85). A po-
tential use for BRD domains is a fusion that binds acetyl
marks and represses target genes. Aberrant histone acetyl-
transferase activity has recently become the focus of novel
anti-inflammatory therapeutics (reviewed in (86)).
The baculovirus inhibitor of apoptosis repeat (BIR) do-
main is an approximately 70 amino acid domain containing
a zinc coordinated by histidine and cysteine residues, and
recognizes phosphorylated histones (87) (reviewed in 88).
BIR domain binding has been determined by X-ray crystal-
lography of full-length BIRC5 bound to H3T3p (87,89,90).
The BIRC5 (Survivin) protein contains a BIR domain that
binds to phosphorylated histone H3 threonine 3 (H3T3p)
by surrounding the first four residues of the peptide with 10
negatively charged residues. The residues from BIRC5 that
make direct contact with the H3 tail are conserved across
vertebrates (89,91). Structural analysis shows that the BIR
domain contains an accessible, preformed binding site for
H3T3p recognition which suggests a rigid scaffold for bind-
ing. This BIR-H3 interaction pattern is highly conserved in
other regulatory proteins that containBIRdomains (87,90).
Studies revealed a consensus binding motif that includes
an N-terminal phosphorylated A-X-S/T-R/K (90) (Figure
3C). Mutational analysis targeting the histone-interacting
residues of BIR resulted in reduced binding and reduced
centromere localization or poor microtubule depolymerase
(MCAK) recruitment in cells (87). Kelley et al. showed that
BIR interacts with its cognate histone PTM in the absence
of other subunits from the chromosomal passenger com-
plex (89). This observation suggests an intrinsic histone-
recognition activity that might enable a BIR fusion protein
to bindH3T3p. NoBIR fusion proteins have been reported,
so this is yet to be determined.
Plant homeodomain fingers (PHD) are a class of diverse
motifs consisting of two 50–80 amino acid domains that
contain a zinc binding site. PHDs generally interact with
histone H3 trimethylated at lysine 4 (92,93). Isolated PHD
fingers from several proteins, such as Yng1 (94), ING2 (95),
TAF3 (96),NURF (97,98), ING3 (99), JARID1A (100) and
DIDO (Death Inducer Obliterator) (60) have shown simi-
lar interactions withH3K4me3 in different crystal structure
studies. The PHD finger of L3MBTL1 recognizes its tar-
get via cavity insertion (101). The PHD domain of DIDO
(Figure 3D), binds H3K4me3 with a noncanonical aro-
matic cage that contains a histidine residue. When aligned
against other PHD fingers known to bind to H3K4me3, all
proteins shared a conserved tryptophan residue (W291 in
full length Dido3) in the aromatic cage, as well as other
residues known to coordinate zinc ions (60). Using struc-
tural information from methyllysine binding, Li et al. en-
gineered a plant homeodomain (PHD) finger, which nor-
mally binds trimethylated lysines (H3K4me3), to preferen-
tially bind me2 and me1. A single mutation (Y > E) in the
aromatic cage responsible for substrate recognition changed
the mode of interaction from cavity insertion to surface
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Figure 3. Structural features of representative histone binding domains and their applications in synthetic systems. (A) The Chromodomain of CBX7 (116),
(B) bromodomain of GCN5 (79), (C) BIRC5 (Survivin) subunit of the Chromosomal Passenger Complex bound to H3T3p (90) and (D) the PHD finger
of Dido3 (60). Green = histone sidechain and PTM, blue sphere = coordinating metal ion. Cartoons below each structure depict the binding domain–
PTM interaction in the context of a whole nucleosome. (E, F) Cartoons illustrate uses of histone-binding domains to design synthetic transcriptional
regulators. Hypothetical applications have italic captions. (E) Synthetic effectors co-regulate all genes (gene 1, 2, ..., n) near a target PTM. This application
could be used to convert silencing PTMs into gene activation and activating PTMs into gene repression. The CD from CBX8 has been used to build a
synthetic reader that targets the H3K27me3 gene-silencing mark and stimulates gene expression through a C-terminal VP64 domain (77,78). (F) Synthetic
regulators could be designed to integrate DNA sequence and PTM information at a specific target gene or allele. (top) Assembly of a split transcriptional
activator requires the binding of two fusions. (bottom) Stable binding of weak DNA binding domain (WDB) requires the presence of a specific PTM. AD
= transcriptional activator domain, RD = transcriptional repressor domain.
groove recognition. PHD motifs can also recognize acetyl-
lysines, as observed for the protein DPF3b which interacts
with H3K14ac (102). PHD motifs retain their intrinsic ac-
tivity in fusion proteins. The oncogenic fusion of nucleo-
porin 98 (NUC98) with the PHD domain from JARID1A
shows broad colocalization with H3K4me3 and accumu-
lates at the H3K4me3-enriched HOXA9 gene in human
cells (100). In a study using mouse cells, an HA-tagged N-
terminal peptide containing the PHD domain from Dido1
(528 aa) was sufficient to rescue the epigenetic activity of the
full length Dido3 isoform (2256 aa) (K. van Wely, personal
communication) and (60)). A mouse model has been gen-
erated to express a DIDO PHD-RFP fusion (60,103), but
neither the subcellular localization nor histone interaction
of this fusion protein have been reported yet.
Allosteric regulation of PTM-binding proteins by small
molecules suggests that chromatin proteins can be designed
to switch between binding and nonbinding states at will.
Tightly-regulated chromatin systems enable insights into
epigenetic dynamics, as seen in other work where a small
molecule (doxycycline) was used to control docking of TetR
fusions at reporter genes (42,64). Gelato et al. described a
H3 binding protein, UHRF1, that is allosterically regulated
to allow or to block binding to modified histones. UHRF1
has two binding states that target either unmodifiedH3 tails
via a homeodomain or H3K3me3 via a tandem tudor do-
main (TTD). In the apo state, a polybasic region on the C
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terminus sterically occupies a binding groove in the TTD,
disrupts interaction with H3K9me3, and allows the home-
odomain to bind to unmodified H3 tails. When UHRF1 is
bound by phosphatidylinositol phosphate at the polybasic
region, a global conformational change is induced, allow-
ing the tudor domain to bind to H3K9me3. This mecha-
nism demonstrates basic allosteric modulation of a histone
reader (104). In summary, mechanistic studies of PTM-
binding protein folds have provided a useful, relatively un-
tapped resource for fusion protein design. The recognition
of specific histone marks could enable broad co-regulation
of sets of genes (Figure 3E). Alternatively, DNA and his-
tone recognition could be coupled to conditionally control
a single gene target based upon the epigenetic state of the
locus or allele (Figure 3F).
MULTIVALENT HISTONE-BINDING DOMAINS INTE-
GRATE MULTIPLE PTM SIGNALS
Natural multivalent PTM-binding proteins and complexes
can interpret multiple epigenetic marks at once and increase
binding affinity for a target histone (26). Structures of these
multivalent proteins have provided insights into how mul-
tivalency can be exploited for synthetic systems. Recogni-
tion of combinatorial PTMs could provide greater speci-
ficity. For instance, Su et al. reported a Kd of 45 nM for
the dual spin/Ssty repeat domains of Spindlin1 for histone
H3 trimethylated at K4 and dimethylated at R8 (H3K4me3-
R8me2) (105). The Kd was lower (139 nM) for an off-target
peptide H3K4me3R8me1. Multivalent binding might com-
pensate for the intrinsic low affinity of interactions be-
tween single PTM-binding proteins and single targets. In
the same investigation, Su et al. observed reduced bind-
ing affinity (22 M) of Spindlin for H3R8me2 alone (105).
The HP1 protein achieves enhanced affinity through self-
dimerization. In a study of HP1 in vitro, mutations that dis-
rupted HP1 self-dimerization showed reduced affinity for
H3K9me3 (106). The dimerizationmotif is also required for
HP1 activity in cells (107,108).
Research of natural and synthetic multivalent domains
suggests principles for designing proteins that recognize
more than one PTM. Spacing and orientation of the PTM-
binding motifs within the protein appears to be critical for
optimal function. The double bromodomain module from
TAFII250 recognizes H4K5acK12ac (Kd of 1.4 M). Inter-
estingly, the distance between the tandem bromodomains
matches the distance between the acetylated residues (109).
In a study of the tandem PHD finger and bromodomain of
BPTF, Ruthenburg et al. observed that the insertion of two
amino acids (QS) into the rigid alpha helical linker region to
rotate the domains 200◦ out of phase disrupted binding to a
doubly-modified nucleosome (94). Mutations in the linker
that added flexibility also impaired bivalent binding, under-
scoring the importance of domain orientation in multiva-
lent interactions.
The arrangement of nucleosomes and histone PTMs at
genomic target regions influences the function of multiva-
lent PTM-binding proteins. The combined contribution of
the PHD finger domain in Rco1 and the chromodomain
in Eaf3 direct the histone deacetylase complex Rpd3S to
active loci that are enriched H3K36me (58,110). Hu et al.
proposed that di-nucleosome recognition reinforces Rpd3S
binding, thus allowing Rpd3S to tolerate fluctuations in
H3K36me levels (111). Optimal binding was achieved in
vitro when the adjacent nucleosomes were 30–40 bp apart
(112). BPTF is another example of a protein that shows a
preference for specific PTMplacement. In experiments with
reconstituted, customized nucleosomes, the divalent PHD-
bromodomain from BPTF showed greater interaction with
histones when the target PTMs were placed on a single nu-
cleosome, compared to PTMs that were distributed across
two nucleosomes (94).
DISRUPTING CHROMATIN: SYNTHETIC ANTAGO-
NISTS OF CHROMATIN COMPLEXES
Chromatin complexes are stabilized by several intramolec-
ular interactions between proteins and histone tails as well
as between subunits within the complex. Molecular antag-
onists have been designed to disrupt chromatin complexes
and alter gene expression states by targeting a core sub-
unit that recruits other binding partners to the gene target.
Polycomb Repressive Complex 1 types 2 and 4 (PRC1.2,
PRC1.4) generally include a histone PTM-binding chro-
mobox (CBX) paralog, RING1A/B, RING1 and YY1-
binding protein (RYBP), and polycomb group ring fin-
ger 2 (PCGF2, Mel-18) or polycomb group ring finger 4
(PCGF4, BMI1) (22) (Figure 4A). Histone deacetylases
(HDACs) support PRC function by removing acetyl groups
from H3K27 to allow methylation, which is recognized by
CBX. These proteins work in concert to support chromatin
compaction and gene silencing, often at tumor suppressors
in cancer cells. To perturb CBX7 activity, inhibitors have
been designed to bind H3K27me (113) or CBX7 (114–116).
Informed by the solved structure ofCBX7 in complexwith a
native peptide or a synthetic inhibitor, Ren et al. performed
an in vitro screen of a library of compounds to identify
CBX7 inhibitors. These compounds (see Figure 4B for an
example) led to de-repression (transcriptional activation)
of CBX7 target genes in human prostate cancer cell lines
(72). An in silico screen identified a structurally unique com-
pound that demonstrated improved cellular activity. When
tested in mouse ES cells, highly specific de-repression of
CBX7 target genes was observed, compared to almost no
impact on non-target genes (72). Simhadri et al. startedwith
trimethyl-lysine peptides and structural data to eventually
develop a peptide to directly bind the CBX7 CD and in-
hibit its function (114) (Figure 4C). In later work, Stuckey
et al. used a molecular dynamics platform to develop a
compound that mimics natural peptide binding to CBX7
(115). Structure-guided work has also led to the discovery
of inhibitors of the paralog CBX6 (117). Lastly, molecu-
lar structures have enabled the discovery of inhibitors of
PTM-modifying enzymes. Whitehead et al. identified class
1 HDAC inhibitors that are selective for the HDAC8 iso-
form (118) (Figure 4D). This work demonstrates that en-
zyme inhibitors can be highly specific while maintaining
biologically-relevant affinities.
BRD2 interacts with acetylated histones, as well as sev-
eral non-histone proteins including glioma tumor suppres-
sor candidate region gene 1 (GLTSCR1), the histone argi-
nine demethylase JMJD6, and histone methyltransferase
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Figure 4. Artificial disruption of multi-protein chromatin complexes. Cartoons depict the context in which inhibitors interact with specific subunits. Shapes
are scaled to reflect relative protein sizes (kiloDaltons). Histone PTM symbols are the same as in Figure 2. Arcs = protein interactions (referenced in the
text), dashed arrows = histone modifying activity, red lines = inhibitor-mediated disruption. (A) The PRC1.2/1.4 type silencing complex can be disrupted
by inhibiting the binding of CBX7 CD to H3K27me3 or by inhibiting the removal of acetyl groups from H3K27 by HDAC8. Examples of CBX7 CD
inhibitors includeMS351 (116) (B) and a synthetic peptide (114) (C). (D) The inhibitor Ligand 4 (118) disrupts HDAC8 activity. (E) BRD2 recruits several
proteins, including histonemodifiers, to stimulate gene activation. Inhibitors such as JQ1 (120) (F) have been designed to disrupt the central histone-binding
activity. (B–D, F) Boxes show sites within chromatin proteins where low molecular weight inhibitors (green) interact with specific residues (red)
NSD3 to stimulate gene expression (119) (Figure 4E). BRD-
containing proteins stimulate MYC oncogene expression
and promote the growth of cancer cells (119). Therefore,
BRD is an important therapeutic target (81). Bromodomain
inhibitors such as JQ1 (120) and I-BET (121) have been
identified in high throughput screens to identify small com-
pounds that fit the histone recognition pocket of BRD2 (1-
473), BRD3 (1-434) and BRD4 (1-477) (121).
A noteworthy example of structure-guided design come
from James et al., who developed strong inhibitors that
bind within the methyl-lysine recognition cavity in malig-
nant brain tumor (MBT) repeat domains (122), and oth-
ers who developed inhibitors of the H3K27 methyltrans-
ferase EZH2 (123,124). Horton et al. determined the struc-
tures of a diverse set of demethylase inhibitors to eluci-
date the molecular mechanism of binding. Their work pro-
vides a general platform for designing epigenetic inhibitors.
Structures of the demethylase complexed with various small
molecules indicated the potential diversity of inhibitors.
The complexes showed a similar binding interfaces but dif-
fered in atomic interactions, such as metal coordinating lig-
ands (125).
Since the first reports of the role of Polycomb proteins
in oncogenesis and metastasis, a multitude of inhibitors
have been developed as epigenetic drugs. Inhibitors of
PTM-generating enzymes and their impact on drug dis-
covery is discussed in several excellent reviews (126–131).
Structure-focused work has illuminated the molecular in-
teractions between inhibitors and PTM-binding proteins
or histone deacetylase enzymes (HDACs). Stuckey et al.
demonstrated that a PRC1 inhibitor could be designed to
inhibit human prostate cancer cell (PC3) proliferation (115).
The structure of the inhibitor is similar to the natural lig-
and H3K27me3 and is highly specific for two chromod-
omains, CBX4 and CBX7. Inhibitors that bind and inter-
fere with bromodomains (BRDs) have been used to con-
trol gene expression in disease-relevant cell culture model
systems. Small molecule-mediated inhibition of BRD was
used to down-regulate MYC transcription in leukemia and
myeloma cells (132,133) and to suppress inflammation in
bone marrow-derived macrophages (121). Recently, in vivo
work has shown that a new BRD-specific inhibitor, MS402,
preferentially binds to the first bromodomain motif within
BET proteins and is therefore more specific than the broad-
acting inhibitor JQ1 (Figure 4F). Cheung et al. demon-
strated the therapeutic potential of MS402 by preventing
and reducing T-cell transfer-induced colitis in mice (134).
These studies underscore the clinical potential for synthetic,
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epigenetic regulation of genes that have therapeutic proper-
ties.
BUILDING CHROMATIN: SCAFFOLDING CHRO-
MATIN COMPLEXES WITH RNA AND DNA
In natural systems, histone-modifying proteins and other
chromatin components are spatially arranged along DNA
strands. Several studies have demonstrated that specific ar-
rangements of these proteins are non-random, highly regu-
lated, and play a role in epigenetic regulation of gene expres-
sion. Chromosome looping, sub-nuclear compartmental-
ization and gene expression can be altered by manipulating
non-coding DNA elements such as the locus control region
(LCR), CTCF-bound insulators, and lamina-associated do-
mains (LADs) (reviewed in Park et al. (26). Here, we dis-
cuss the two classes of epigenetic scaffold elements that have
been rigorously analysed within synthetic systems: Poly-
comb Response Elements and long non-coding RNA.
Polycomb Response Elements (PREs) are cis-regulatory
DNA sequences that recruit chromatin complexes to clus-
ters of genes. Robust epigenetic control through PRE ac-
tivity is required to stabilize distinct transcription profiles
within subpopulations of cells (135). Drosophila PREs con-
tain clusters of short motifs that interact with several chro-
matin proteins including Pleiohomeotic (PHO), Zeste pro-
tein, GAGA factor (GAF), Dsp1 and others (135). A re-
markable characteristic of PREs is ‘epigenetic memory’, the
ability to confer a stable silenced or active state at nearby-
genes after removal of the inducer of either state. Early work
in Drosophila demonstrated that a PRE called Fab-7 could
be used to switch the expression state at an adjacent reporter
gene from active to silenced and vice versa (136–138). These
artificially-induced expression states persisted over several
rounds ofmitosis andmeiosis.WhileDrosophila PREs have
been well documented (139), discovery of human PREs has
been elusive (140) until recently. In 2010, Woo et al. identi-
fied a noncoding PRE-like DNA element from the human
HOXD gene region (141). When this element, D11.12, was
placed upstream of a luciferase reporter, the transgene be-
came enriched for repressive histone PTMs and silencing-
associated proteins and luciferase expression was reduced
to <5% of the active state. Since this discovery, other hu-
man PREs have been identified (142). Experiments have
shown that PRE function can be ported from onemetazoan
species into another, demonstrating that epigenetic mem-
ory is an inherent property of PRE DNA fragments. For
instance, mammalian PRE candidates have been validated
based on their activity in Drosophila. PREs that were iden-
tified in studies of human T cells (143) or themouse genome
(144,145) showed Polycomb protein binding and repression
of a reporter gene in transgenic flies.
Investigations of PREs provide some guidance on how
these elements can be used to control synthetic genetic sys-
tems. In Drosophila, artificially-induced states mediated by
PREs can persist over timescales of metazoan tissue de-
velopment, a characteristic that is critical for the practi-
cal use of synthetic gene circuits in multicellular organ-
isms. An important outstanding question for PRE-based
genetic engineering is to what extent the behavior of a
PRE can be customized to generate distinct gene expression
patterns. Mounting evidence from studies in Drosophila
show that PREs respond to inducers either early or late
in development, and are sensitive or insensitive to their
genomic location (reviewed in (140)). Multiple short mo-
tifs of varying copy number and order can be found in
PREs fromDrosophila (146,147) andmammalian genomes
(135,141,142) (Figure 5A). Therefore, it is tempting to
surmise an underlying protein-scaffolding code. However,
current models for PRE function are incomplete. For in-
stance, no human orthologs have been identified for two
key Drosophila PRE-recognition proteins, GAF and Zeste
(Figure 5A). The Drosophila protein Dsp1 and the human
ortholog HMGB2 (hHMG2) have been linked to PRE ac-
tivity, but there is conflicting evidence for the DNA se-
quence motif that is recognized by the proteins (135). Fi-
nally, although the number of motifs can be identified
within a PRE, the stoichiometry of proteins per PRE is not
precisely defined. If a deterministic code is eventually iden-
tified, artificial PREs could be designed to control the mag-
nitude and dynamics of epigenetic expression in synthetic
genetic constructs.
Reminiscent of PREs, synthetic DNA constructs can be
designed to include combinations of short DNAmotifs that
are recognized by transcriptional regulators. Artificial op-
erators have been constructed de novo from protein-binding
motifs found in well-studied bacterial operons (e.g. Tet, lac,
trp) (148) as well as eukaryotic loci (e.g. yeast Gal4 UAS,
Zinc finger recognition sites) (149). These motifs can be
arrayed within a synthetic DNA fragment and placed up-
stream of a target gene. Chromatin fusion proteins that rec-
ognize themotifs assemble at the scaffold based on the num-
ber and arrangement of motifs. Keung et al. used two or-
thogonal Zinc finger (ZF) adapters to co-recruit pairs of
gene-regulating proteins to a single promoter (150) (Figure
5A). Although this study was limited to observing synergy
or antagonism between single chromatin proteins and the
ZF-VP16 activator, the synthetic ZF platform has potential
for more general use, i.e. to control spatial arrangements of
pairs or larger combinations of chromatin proteins.
Long noncoding RNAs (lncRNAs) also act as modu-
lar scaffolds for multi-protein complexes. The underlying
design principles of these elements are just beginning to
emerge. Engreitz et al. provide a superb review of lncRNA
structure and function in the context of chromatin and
epigenetics (151). Here, we highlight examples of well-
defined modular lncRNAs may eventually inform synthetic
RNA scaffold design. The lncRNA known as HOTAIR
(HOX transcript antisenseRNA) has twomodules with sec-
ondary structures that each interact with distinct histone-
modifying complexes to maintain transcriptional repres-
sion (152). The 5’ domain of HOTAIR binds the PRC2
complex that generates H3K27me3, while the 3’ domain
binds the LSD1/CoREST/REST complex that stimulates
H3K4 demethylation (153). The 5’ domain is a distinct
module with intrinsic PRC2 binding activity. Structural dis-
section of HOTAIR revealed that nucleotides 1–300 are suf-
ficient for interaction with PRC2 (153) and that a core mo-
tif of 89 nucleotides is required for binding (154). However,
recent work has shown that the role of PRC2 is dispens-
able for HOTAIR-mediated silencing (155). The lncRNA
Firre (functional intergenic repeating RNA element) con-
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Figure 5. Scaffolding of chromatin proteins on DNA or RNA. (A) Natural Polycomb response elements (top) include combinations of short motifs that
are recognized by non-histone chromatin proteins. Known PRE-binding proteins and DNA core motifs are shown for Drosophila and mammals. Crystal
structure data (168) (top right) shows that YY1 (human PHO homologue) interacts with DNA via a zinc finger motif. A synthetic operator (bottom)
designed by Keung et al. is shown as an example of a synthetic DNA chromatin scaffold. Nucleotides are named according to the IUPAC code. CP =
chromatin protein, ZF = zinc finger. (B) HOTAIR (top) is an example of a natural RNA chromatin scaffold. Its 3’ and 5’ regions act as modules for PRC2
and LSD1/CoREST/REST recruitment. The role of PRC2 (dashed circle) may be dispensable for HOTAIR function (154). LSD1 residues 171–317, 571–
654 and 769–836 and RNA (UUAGG) are shown from the crystal structure model (169). Two CRISPR/dCas9-based RNA scaffolds (bottom) are shown
as examples of synthetic RNA scaffold systems (158). AD = activation domain.
tains twelve tandem repeats of an RNA motif that binds
the nuclear matrix protein HNRNPU, also known as SAFA
(scaffold attachment factor A) (156). The structure of Firre
demonstrates that tandem replicate RNA modules can op-
erate as independent units, allowing several proteins to co-
occupy a single RNA scaffold. Xist is an example of a
lncRNA that interacts with a with a DNA-binding pro-
tein as well as other chromatin proteins. SAFA acts as a
DNA-binding module that tethers the Xist RNA–protein
complex toDNA sequences (Figure 5B). TheRNA-binding
arginine–glycine–glycine (RGG) domain of SAFA is re-
quired for interaction with Xist (157). Chromatin proteins
may recognize a variety of RNA sequences and secondary
structure conformations. Mounting evidence is beginning
to shed light on the mechanistic details of protein-lncRNA
binding, but there is not sufficient information to engineer
lncRNA-derived systems (158).
Scientists must first identify core RNA subunits with in-
trinsic, portable activity before we can use lncRNAs for syn-
thetic systems. For an immediate solution, researchers have
turned to protein-RNA modules from well-understood vi-
ral systems to design lncRNA-inspired gene regulators. Za-
latan et al. used the viral RNA stem-loop hairpins MS2,
PP7 and com to build a scaffold that was recognized by
the proteins MCP, PCP and Com respectively (Figure 5B).
They targeted the scaffold to a specific gene by using a
CRISPR/dCas systemwhere theDNA-binding guideRNA
(gRNA) included a long RNA extension with different
combinations of the viral hairpins. The group demonstrated
epigenetic repression of a target gene by recruiting KRAB-
Com fusion to a comRNA hairpin (159). The RNA hairpin
adapters are also functional in tandem (Figure 5B), which
suggests that this system could be used to recruit combina-
tions of chromatin proteins to a single locus.
CONCLUSIONS AND FUTURE OUTLOOK: BEST
PRACTICES FOR CHROMATIN ENGINEERING
We have described recent advances in synthetic, chromatin-
derived systems and the fundamental research discoveries
that have preceded and enabled the development of these
technologies. In this section we will discuss important next
steps and opportunities for continued advancement of chro-
matin engineering.
Deeper understanding of the consequences of artificial
post-translational modifications (PTMs) on chromatin is
critical to advance synthetic PTM technology. Exploratory
studies should determine the impact of customizable pa-
rameters such as the relative position of the PTMnucleation
site to the target gene, rate of PTM production, and the
interactions between PTMs and regulators at single target
sites. Recent studies have demonstrated the value of system-
atically adjusting design parameters. For instance, Hilton
et al. placed the active core domain of the p300 acetyl-
transferase at different distances from the target gene and
observed significant activation of genes at distal enhancers
and regulatory regions up to 46 kb from the transcrip-
tional start site (49). Bintu et al. determined the kinetics of
four distinct silencing regulators (EED, KRAB, HDAC4,
DMNT3B) in single CHO-K1 cells to identify conditions
that generally enable silencing of a predetermined degree
and duration (42). Amabile et al. recruited combinations
fusion proteins to a single gene to compare silencing in-
duced by one, two or three repressors (KRAB, DMNT3a,
DNMT3L). Two or three repressors generated long-term
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Figure 6. Workflow to discover modular, reusable chromatin-derived peptides that bind histone PTM’s. FP = fluorescent protein, HRP = horseradish
peroxidase-conjugated antibody, Mam. vector = mammalian expression vector, ED = effector domain.
silencing at endogenous genes in human HEK293T, K562
and B-lymphoblastoid cells, human primary T lympho-
cytes, and mouse NIH-3T3 cells (64). In a study of KRAB
and Sss1 co-recruitment, synergy was dampened by compe-
tition of each effector for shared cofactors (41). This work
revealed an important caveat in using components from
overlapping pathways. Keung et al. recently reported an im-
pressive study in which 223 PTM-generating fusion proteins
enhanced, antagonized, or did not affect the function of a
VP16 activator at a target reporter gene in yeast (150). Pio-
neering efforts such as the studies highlighted here provide
a glimpse of the exciting work yet to be done. In addition
to customizable parameters, uncontrollable events such as
cross-talk between PTMs, enzyme co-recruitment and the
impact of these processes on gene expression states (dis-
cussed previously in this review) must also be considered
andmeasured tomaximize the value of the results from syn-
thetic studies.
Customization of non-enzymatic chromatin proteins rep-
resents an expansive design space that has barely been ex-
plored. In order to accelerate the pace of discovery, scien-
tists should develop and share workflows to efficiently parse
large libraries of synthetic protein candidates. As an exam-
ple, we present a workflow that is under development in our
lab. We begin with a large library of fusion protein vari-
ants and carry out protein–histone peptide interaction tests
in vitro (ELISA) to identify functional candidates (Figure
6). Candidates that show preference for the target histone
PTM in the first-pass test are used to build synthetic gene
regulators. We then expose a PTM-bearing reporter gene to
the synthetic regulator to validate its function in live cells.
This workflow allows us to identifymodular, reusable PTM-
binding domains to aid in the design, construction, and ap-
plication of synthetic, chromatin-derived proteins. In ad-
dition, we use peptide arrays to determine cross-reactions
with various histone PTMs and to calculate affinities for
each target. So far, our workflow has demonstrated the
interaction of a Polycomb Chromodomain fusion (PCD-
mCherry) with H3K27me3 in vitro (not published), which
corroborates previous studies of this fusion protein in live
cells (77,78). We expect ongoing work to identify new vari-
ants with interesting properties, such as enhanced affinity
for H3K27me3.
A challenge for practical and reliable use of PTM-binding
domains in living cells (e.g. as illustrated in Figure 3E and
F) is the broad and varying distribution of histone mod-
ifications throughout the genome over time and at differ-
ent stages of cell development. Therefore, it is important
to carefully consider the histone PTM target from a sys-
tems viewpoint rather than as a single gene, as is the case
for DNA-binding regulators. For instance H3K27me3, the
target of the PCD motif, appears at thousands of genes
and many non-coding regions in human cells. The real util-
ity of regulating a cohort of this size may not be immedi-
ately obvious. However, a single PTM might not be suf-
ficient to support artificial regulation of the entire set of
genes. We have observed that a regulator fused to the PCD
from CBX8 affects only a subset of all H3K27me3-positive
genes (77,78) and that many of these genes are near bi-
valent H3K27me3/H3K4me3-marked promoters (78). The
key lesson from this example is that simple assumptions
about epigenetic targets should be tested by using integrated
transcriptomic and epigenomic analyses. The identification
of predictive epigenetic signatures at target genes will en-
able practical use of PTM-binding proteins for synthetic
systems.
Eventually, new chromatin engineering toolsmay become
available for human and animal health applications. The
safety and efficacy of these tools will need to be determined
in the context of a complex epigenome. Therefore, it is crit-
ical to determine the global impact of the synthetic compo-
nent on genome-wide expression levels in order to identify
off-target or broad effects. Evidence fromHDAC inhibition
experiments in pancreas cells (160–164) suggest that gener-
ating activation-associated PTMs at key genes could trans-
differentiate alpha cells into beta cells, boost insulin pro-
duction in pancreatic tissue, and cure diabetes. The RNA-
seq data from Bramswig et al. show that dozens of genes
that are not involved in the insulin production pathway are
also affected (162). Nyer et al. used RNA-seq and ChIP-
seq to determine that a broad-acting H3K27me3-binding
synthetic regulator reactivated silenced tumor suppressors
as well as hundreds of other genes (78). The data from
the pancreas and cancer cell studies should be further ex-
plored to determine the long-term impact of broad changes
in gene expression on cell phenotype. Even in cases where
the synthetic chromatin protein binds a single unique DNA
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target, chromatin modifications nucleated at one site can
spread into neighboring loci (discussed in (49)). To verify
target specificity of a Cas9-p300 histone acetyltransferase
fusion protein, Hilton et al. performed RNA-seq to identify
cases where only the target gene was activated and no other
genes were affected (49). It is imperative that synthetic biol-
ogists and chromatin engineers include genome-wide anal-
ysis, bioinformatics, and gene network analysis in their ar-
senal of research techniques.
Synthetic epigenetic research is still in its infancy. The
plethora of structural and biochemical data that describe
histone-modifying enzymes, histone PTM-binding pro-
teins, and modular nucleic acid scaffolds present an op-
portunity to expand the bioengineering toolbox. Histone
PTMs represent a rich set of biological information that can
be exploited for gene targeting and cellular regulation. Ge-
nomic profiling can be coupledwith chromatin protein engi-
neering to identify and manipulate epigenetically-regulated
target sites. While some epigenetic fusion constructs have
been successfully used to activate or repress target genes,
the number of utilized domains represents a small fraction
of well-characterized PTM binding and modifying proteins
(80,149). So far, most of the reported synthetic epigenetic
systems are limited to specific regulation of a single ge-
netic locus using PTM modifying enzymes that are fused
to DNA-binding domains. Histone PTM-binding proteins
fused with effector domains, which have been explored less,
could enable co-regulation of many genes at once. The ef-
forts summarized in this review represent important, initial
advances into a vast exploration space of potential chro-
matin protein designs and applications. Chromatin is a cen-
tral mechanism for precise and reliable control of genes that
drive multicellular development. Maturation of the syn-
thetic epigenetics field will produce new technologies and
discoveries that will have significant impacts on genetic re-
search, agricultural science and biomedical engineering.
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